Company Info

Astellas

Drug Discovery & Development

Overview

Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products.

Contributions

Contributors

Contributions

11 Contributions1 / 1

M&A

Astellas Strengthens Immuno-oncology Pipeline with Acquisition of Xyphos Biosciences, Inc.

Astellas

PR-M01-20-NI-006Jan 3, 2020

License Agreement

Astellas and Frequency Therapeutics Enter into License Agreement for FX-322, a Regenerative Treatment Candidate for Hearing Loss

Astellas

PR-M07-19-NI-055Jul 22, 2019

BLA

Astellas and Seattle Genetics Announce Submission of Biologics License Application to FDA for Enfortumab Vedotin

Astellas

PR-M07-19-NI-050Jul 19, 2019

Launch

Astellas Launches PROGRAF® Granules (tacrolimus for oral suspension) in the U.S. for Pediatric Liver, Heart, and Kidney Transplant Patients

Astellas

PR-M03-19-NI-051Mar 19, 2019

Collaboration

Astellas and WiserCare Announce Collaboration to Improve Patient Experience

Astellas

PR-M02-19-NI-057Feb 26, 2019

Launch

Astellas Launches XOSPATA® (gilteritinib) in the U.S. for the Treatment of Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) with a FLT3 Mutation

Astellas

PR-M12-18-NI-057Dec 17, 2018

Leukemia

Astellas Presents Updated Results from Phase 1 Study of Gilteritinib Plus Chemotherapy in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

Astellas

PR-M12-18-NI-025Dec 7, 2018

Launch

Astellas Global Health Foundation Launches

Astellas

PR-M11-18-NI-087-3340Nov 26, 2018

FDA Approval

U.S. FDA Approves XTANDI® (enzalutamide) for the Treatment of Men with Non-Metastatic Castration-Resistant Prostate Cancer (CRPC)

Astellas

PR-M07-18-NI-047Jul 16, 2018

Appointment

Astellas names Nahrin Marino to Vice President, Head of Ethics & Compliance Americas

Astellas

PR-M06-18-NI-031Jun 11, 2018

FDA

U.S. FDA Grants Priority Review for a Supplemental New Drug Application (sNDA) for XTANDI® (enzalutamide) in Non-Metastatic Castration-Resistant Prostate Cancer (CRPC)

Astellas

PR-M03-18-NI-085Mar 23, 2018

1 / 1

0 Contributors1 / 0

No authors found

1 / 0

Nice Insight is the market research division of That's Nice LLC, the leading marketing agency serving life sciences.

Explore

About Us Nice Insight That's Nice

Reach Our Team

My Account

Subscribe for the newsletter

Subscribe for the Newsletter

Mobile Navigation

Company Info

Astellas

Drug Discovery & Development

Overview

M&A

Astellas Strengthens Immuno-oncology Pipeline with Acquisition of Xyphos Biosciences, Inc.

Astellas

License Agreement

Astellas and Frequency Therapeutics Enter into License Agreement for FX-322, a Regenerative Treatment Candidate for Hearing Loss

Astellas

BLA

Astellas and Seattle Genetics Announce Submission of Biologics License Application to FDA for Enfortumab Vedotin

Astellas

Launch

Astellas Launches PROGRAF® Granules (tacrolimus for oral suspension) in the U.S. for Pediatric Liver, Heart, and Kidney Transplant Patients

Astellas

Collaboration

Astellas and WiserCare Announce Collaboration to Improve Patient Experience

Astellas

Launch

Astellas Launches XOSPATA® (gilteritinib) in the U.S. for the Treatment of Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) with a FLT3 Mutation

Astellas

Leukemia

Astellas Presents Updated Results from Phase 1 Study of Gilteritinib Plus Chemotherapy in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

Astellas

Launch

Astellas Global Health Foundation Launches

Astellas

FDA Approval

U.S. FDA Approves XTANDI® (enzalutamide) for the Treatment of Men with Non-Metastatic Castration-Resistant Prostate Cancer (CRPC)

Astellas

Appointment

Astellas names Nahrin Marino to Vice President, Head of Ethics & Compliance Americas

Astellas

FDA

U.S. FDA Grants Priority Review for a Supplemental New Drug Application (sNDA) for XTANDI® (enzalutamide) in Non-Metastatic Castration-Resistant Prostate Cancer (CRPC)

Astellas

No authors found

No authors found

M&A

Astellas Strengthens Immuno-oncology Pipeline with Acquisition of Xyphos Biosciences, Inc.

Astellas

License Agreement

Astellas and Frequency Therapeutics Enter into License Agreement for FX-322, a Regenerative Treatment Candidate for Hearing Loss

Astellas

BLA

Astellas and Seattle Genetics Announce Submission of Biologics License Application to FDA for Enfortumab Vedotin

Astellas

Launch

Astellas Launches PROGRAF® Granules (tacrolimus for oral suspension) in the U.S. for Pediatric Liver, Heart, and Kidney Transplant Patients

Astellas

Collaboration

Astellas and WiserCare Announce Collaboration to Improve Patient Experience

Astellas

Launch

Astellas Launches XOSPATA® (gilteritinib) in the U.S. for the Treatment of Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) with a FLT3 Mutation

Astellas

Leukemia

Astellas Presents Updated Results from Phase 1 Study of Gilteritinib Plus Chemotherapy in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

Astellas

Launch

Astellas Global Health Foundation Launches

Astellas

FDA Approval

U.S. FDA Approves XTANDI® (enzalutamide) for the Treatment of Men with Non-Metastatic Castration-Resistant Prostate Cancer (CRPC)

Astellas

Appointment

Astellas names Nahrin Marino to Vice President, Head of Ethics & Compliance Americas

Astellas

FDA

U.S. FDA Grants Priority Review for a Supplemental New Drug Application (sNDA) for XTANDI® (enzalutamide) in Non-Metastatic Castration-Resistant Prostate Cancer (CRPC)

Astellas